OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
27 September 2021 - 9:17PM
OKYO (LSE: OKYO), the life sciences and biotechnology company
focused on the discovery and development of novel molecules to
treat inflammatory dry eye diseases and chronic pain, is pleased to
announce that at the Annual General Meeting, which was held at
10:00 a.m. today, all resolutions were duly passed.
The results of the proxy voting will be
available shortly on the Company's website,
https://www.okyopharma.com/news.
About OKYO Pharma Limited
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is
a life sciences and biotechnology company admitted to listing on
the standard segment of the Official List of the UK Financial
Conduct Authority and to trading on the main market for listed
securities of London Stock Exchange plc. OKYO is focusing on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495
2379
For further information, please visit the
Company's website at www.okyopharma.com.
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024